Effect of chronic use of tadalafil on prostate-specific anti-gene and oxidative stress in obese diabetic patients
A strong and independent association between obesity, diabetes mellitus and elevation of specific prostate – antigene has been widely evidenced in several clinical epidemiologic studies. Preclinical animal models have provided a great deal of information on potential common pathogenic mechanisms underlying these clinical identities. Phosphodiesterase-5 (PDE-5) inhibitors restore NO signaling may improve metabolic parameters through a number of mechanisms. We hypothesized that daily administration of the PDE-5 inhibitor; Tadalafil 10 mg daily will improve metabolic parameters, oxidative stress markers, anti-inflammatory parameters, PSA and body weight in obese diabetic patients and these parameters decreases serum level of prostate –specific anti-gene. Totally, 25 obese diabetic male patients with metabolic syndrome treated with Tadalafil 10 mg daily for three months. Body weight, FPG levels, HbA1C, HOMA-IR, serum prostate-specific antigene, IL-6 and oxidative stress markers were determined monthly. Treatment with tadalafil caused a reduction in fasting glucose levels, HbA1c, HOMA-IR, IL-6, PSA, oxidative stress markers and body weight which were significantly reduced. Tadalafil 10 mg therapy once daily is a safe and effective treatment option for benign prostate hyperplasia glycemic control, and body mass index in diabetic patients with metabolic syndrome.
Full Text Attachment